Currently Viewing:
Supplements Understanding the Current Unmet Needs in Acute Myeloid Leukemia Management and Evolving Treatment Approaches
Unmet Clinical Needs and Economic Burden of Disease in the Treatment Landscape of Acute Myeloid Leukemia
Megan Wiese, MS, PA-C, and Naval Daver, MD
Currently Reading
Current and Emerging Therapies for Patients With Acute Myeloid Leukemia: A Focus on MCL-1 and the CDK9 Pathways
Lindsey Lyle, MS, PA-C, and Naval Daver, MD

Current and Emerging Therapies for Patients With Acute Myeloid Leukemia: A Focus on MCL-1 and the CDK9 Pathways

Lindsey Lyle, MS, PA-C, and Naval Daver, MD
Acute myeloid leukemia (AML) is an aggressive hematologic malignancy that largely impacts the elderly population. Not all AML patients are candidates for the mainstay induction and consolidation treatment options. In addition, despite available therapies, most patients will eventually relapse on, or be refractory to, standard induction therapy, with limited subsequent choices and poor prognosis. Recently, several new and emerging therapies, with a variety of mechanisms of action, have broadened the treatment landscape in newly diagnosed and relapsed/refractory (R/R) AML, providing patients and healthcare providers with more options and several targeted treatment approaches. Preclinical data indicate that the anti-apoptotic protein myeloid cell leukemia-1 (MCL-1) is important to AML cell survival. Cyclin-dependent kinase 9 (CDK9), a transcriptional activator necessary for the expression of MCL-1, represents a promising target for future AML therapies. A number of CDK9 inhibitors, as well as several direct MCL-1 inhibitors, are currently in clinical or preclinical development. The CDK9 inhibitors alvocidib, atuveciclib, and TG02 have completed phase 1/2 clinical trials, with results available for the alvocidib trial showing improved complete remission rates (70% vs 46%; P = .003) for alvocidib in combination with cytarabine and mitoxantrone, versus cytarabine/daunorubicin, in patients with newly diagnosed AML. In addition, several phase 1 clinical trials with CDK9 inhibitors are currently recruiting for treatment of advanced AML. A phase 1b study is also ongoing to investigate alvocidib in combination with B-cell lymphoma-2 inhibitor venetoclax for R/R AML. Although further research is needed, CDK9 inhibitors represent a promising new approach for the treatment of AML.
Am J Manag Care. 2018;24:-S0
Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy that can affect individuals of any age but is most frequently diagnosed in those aged 65 to 74 years, with a median age at diagnosis of 68 years.1,2 AML is the most common acute leukemia in adults but represents approximately 1.1% of all new cancer cases in the United States.1,2 AML can arise de novo or from other factors, including previous cytotoxic or radiation therapy or from antecedent hematologic disorders.2 Prognosis is generally poor and worsens with advanced age.1,3 Poor prognosis is associated with certain chromosomal and genetic aberrations (ie, complex karyotype, MLL rearrangements, FLT3 mutations).4 Novel, targeted treatment options are urgently needed for AML to prolong survival and improve patient outcomes.2

Standard-of-Care Therapy for AML

Current first-line treatment options for AML include induction chemotherapy. The goals of induction therapy in AML are to reduce leukemic burden by inducing complete remission (CR) and to restore normal hematopoiesis.2 The primary option for induction therapy in the first-line AML setting has been for many years the “7 + 3” regimen, composed of 7 days of cytarabine, an analog of cytosine that incorporates into DNA during replication and inhibits DNA synthesis, and 3 days of an anthracycline, one in a cytotoxic class of drugs with multiple mechanisms of action, including DNA intercalation, inhibition of topoisomerase II, and generation of free radicals.5-8

Recently, several new drugs with varied mechanisms of action have been approved by the FDA for the treatment of AML in the first-line setting, adding to the treatment options for patients and healthcare providers. These include midostaurin, a small-molecule multiple tyrosine kinase inhibitor with FMS-like tyrosine kinase 3 (FLT3) inhibitory activity; CPX-351, a fixed-combination of daunorubicin and cytarabine; and gemtuzumab ozogamicin, a CD33-directed antibody-drug conjugate (Table 1).9-16 Emerging therapeutic options include venetoclax, a small-molecule inhibitor of anti-apoptotic B-cell lymphoma-2 (BCL-2) protein.17-19

Venetoclax in combination with low-dose cytarabine has received a breakthrough therapy designation from the FDA for use in frontline therapy in elderly patients with AML who are not eligible for intensive chemotherapy.20 Venetoclax has also been granted FDA breakthrough therapy designation for use with hypomethylating agents as frontline therapy in elderly patients with AML who are not eligible for intensive induction therapy.21 Venetoclax is also being studied in combination with dose-modified intensive chemotherapy.22 Furthermore, the histone deacetylase inhibitor pracinostat, plus azacitidine, received a breakthrough therapy designation from the FDA in August 2016 for use in elderly patients with AML who are not eligible for induction therapy.23

Consolidation therapy in AML generally consists of chemotherapy to maintain control of the disease or hematopoietic stem cell transplantation as a potentially curative option in certain patients.5,24 However, many patients with AML are not considered to be candidates for current treatment strategies because of significant comorbidities, poor performance status, and older age, among other factors.3,25 In addition, available therapies are not effective for all patients, and resistance to and/or relapse on chemotherapy is common. Depending on a variety of factors, including age and type of induction therapy, only approximately two-thirds of patients achieve CR after induction therapy, and the majority will relapse or die from their disease.24,26,27

Several new and emerging therapies are now available or under investigation in the relapsed/refractory (R/R) setting, which may help to improve the prognosis of certain patients with R/R disease. These therapies include enasidenib, a small-molecule inhibitor approved by the FDA in 2017 for patients with R/R AML with an isocitrate dehydrogenase-2 (IDH2) mutation; ivosidenib, an investigational small-molecule inhibitor for the treatment of patients with R/R AML with an isocitrate dehydrogenase-1 (IDH1) mutation; and quizartinib, gilteritinib, and crenolanib, investigational small-molecule inhibitors for the treatment of patients with R/R AML with an FLT3 mutation (Table 2).17-23, 28-41

Targeting Apoptosis as a Therapeutic Approach in AML

Historically, the primary mechanism of action of treatments for AML, in particular the 7 + 3 regimen, has involved the disruption of cell proliferation.6,7 With progress being made in elucidating the underlying biology behind AML, new potential treatment strategies are being identified. Targeting anti-apoptotic proteins, such as myeloid cell leukemia-1 (MCL-1), could positively impact the balance of pro- versus anti-apoptotic proteins and result in increased death of cancer cells and improved disease control.42,43

MCL-1 in AML

MCL-1 is a member of the BCL-2 family of apoptosis-regulating proteins. MCL-1 blocks pro-apoptotic proteins, such as BAK and BAX, thereby preventing programmed cell death through apoptosis.44 Preclinical studies have suggested a role for MCL-1 in the disease etiology of AML. Clinical samples (leukemic blasts and primary human hematopoietic subsets) from 111 patients with AML demonstrated high levels of  MCL-1 protein expression.43

MCL-1 levels have been observed to increase by approximately 2-fold at the time of disease recurrence compared with pretreatment (n = 19).45 Patients with increased MCL-1 levels have showed poor prognosis and/or response to chemotherapy, suggesting that at least some AML malignancies are MCL-1 dependent.45 Downregulation of MCL-1 has been shown to result in the death of murine and human AML cells.42 MCL-1 has also been found to be important for the survival of leukemia stem cells, further underscoring the importance of MCL-1 in the survival of AML cancer cells.46

Preclinical data also suggest possible activity of some agents in targeting multiple pathways. The kinase inhibitor PIK-75 has been found to inhibit both cyclin-dependent kinases (CDK) and BCL-2 family members, inducing apoptosis in a BAK-dependent mechanism.47 Another kinase inhibitor, TG02, has been found to inhibit multiple CDK members as well as other, frequently mutated genes in hematologic malignancies, including janus kinase 2 (JAK2) and FLT3.48

Given the findings of these preclinical studies, targeting MCL-1 seems a reasonable approach for future AML therapies. The short half-life of MCL-1 should be considered as a possible attribute because inhibition of MCL-1 synthesis should rapidly reduce levels of the protein.44 In addition, MCL-1 expression is tightly regulated, suggesting that regulators of expression would be potential targets for new therapies.49 The promising preclinical data and the feasibility of MCL-1 as a possible target of treatment suggest a possible future role for MCL-1 as a biomarker in personalized cancer therapy.45,50

Potential Targets for Reducing Levels of MCL-1

Strategies to reduce MCL-1 expression include direct targeting of MCL-1 and indirect targeting by disruption of transcription/translation. Small-molecule inhibitors are currently in development to directly target MCL-1 and other BCL-2 family members with similar topologies (Table 3).51-55 The second possible avenue—and the overall focus of this report—is targeting the synthesis of

MCL-1, which could involve multiple components, including the promoter sequence, transcription/translation machinery, and transcription/translation regulators.

MCL-1 transcription is controlled by the positive transcription elongation factor b (P-TEFb) complex. P-TEFb, which is made up of CDK9 and cyclin T proteins, activates transcription elongation of multiple genes, including MCL-1.56 CDK9, a transcriptional activator, contains a catalytic domain and phosphorylates the C-terminal domain of RNA polymerase II to activate transcription and elongation, while the cyclin T protein stabilizes CDK9 and plays a regulatory role.57,58  BRD4, a bromodomain protein, anchors the P-TEFb complex to the DNA strand and acts as a positive regulator of transcription.59 CDK9, which is part of a large family of CDKs, represents a possible therapeutic target for reducing MCL-1 synthesis (Figure 1).60-67 Inhibition of CDK9 is known to prevent phosphorylation of the RNA polymerase II C-terminal domain, suggesting that inhibiting CDK9 may prevent the production of anti-apoptotic protein MCL-1, thereby increasing apoptosis.47 Several CDK9 inhibitors are in exploratory and clinical development (Table 4).48,61,63-77

Preclinical and Clinical Evidence of CDK9 Inhibition in AML

As shown in Table 4, a number of CDK9 inhibitors are in development, most in early-stage clinical or preclinical studies.48,61,63-77 TG02, a multi-kinase inhibitor of CDKs, including CDK9, has preliminary results from a dose-escalation phase 1 trial in advanced hematologic malignancies or newly diagnosed AML, which identified a maximally tolerated dose of 50 mg daily.68 Treatment-related adverse events (AEs)  included nausea (42%), vomiting (23%), fatigue (18%), decreased appetite (15%), constipation, and diarrhea (13% each).68


Copyright AJMC 2006-2019 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
Welcome the the new and improved, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up